|Videos|November 20, 2020
Treating Cognitive Impairment in Patients with Schizophrenia
Author(s)David Margolin, MD, PhD
A recent drug trial yields encouraging results.
Advertisement
Schizophrenia can be accompanied by significant cognitive impairments. In this Mental Health Minute, Dr Margolin discusses the results of a Phase 1b clinical trial of a drug meant to treat these issues.
The drug in question, Cerevance's investigational compound CVN058, significantly improved biomarkers of cognitive impairments in patients suffering from schizophrenia. Dr Margolin discusses the structure of the drug trial, details the science behind the drug itself, and previews the next steps of his research.
Dr Margolin is senior vice-president, clinical and translational medicine at Cerevance, Inc.
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Psychiatric Times
1
Podcast: Early Intervention & Psychopharmacology in Bipolar Disorder With Robert M. Post, MD
2
New Positive Phase 2 Topline Data on Elunetirom for the Treatment of Bipolar Depression
3
Suicide Risk Assessment in Patients Denying Suicidal Intent
4
Adjunctive Atypical Antipsychotics in Major Depressive Disorder: Comparing Efficacy and Tolerability
5